^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 overexpression + HR positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    2ms
    Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=67, Active, not recruiting, Immunitas Therapeutics | Recruiting --> Active, not recruiting | N=151 --> 67 | Trial completion date: Apr 2025 --> Jan 2026 | Trial primary completion date: Apr 2025 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability)
    |
    BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation • HER-2 overexpression + HR positive
    |
    Fruzaqla (fruquintinib) • IMT-009
    4ms
    SAFIR 03: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (clinicaltrials.gov)
    P2, N=162, Active, not recruiting, UNICANCER | Recruiting --> Active, not recruiting
    Enrollment closed • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive
    |
    Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • triptorelin
    4ms
    Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada. (PubMed, Clin Breast Cancer)
    Immigration status was not associated with the receipt of appropriate treatment amongst early-stage Her2-positive or TNBC breast cancer in Ontario.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 overexpression • HER-2 overexpression + HR positive • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab)
    4ms
    Clinical and molecular landscape of metastatic extramammary Paget's disease. (PubMed, Oncologist)
    This study highlights the unique molecular and biological features of metastatic EMPD, emphasizing the need for tailored treatment approaches. This information should be used to guide future clinical strategies for metastatic EMPD.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • HR positive • HER-2 overexpression • HER-2 overexpression + HR positive
    |
    nCounter® Breast Cancer 360™ Panel
    5ms
    The expression of epidermal growth factor receptor 2 and its relationship with tumor-infiltrating lymphocytes and clinical pathological features in breast cancer patients. (PubMed, Open Life Sci)
    TIL levels in HER-2-positive BC patients were positively correlated with both HER-2 and CD8 expression. TIL levels were closely related to the prognosis of BC patients, which may provide a theoretical basis for precision treatment in BC.
    Journal • Tumor-infiltrating lymphocyte
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8)
    |
    HER-2 positive • HER-2 expression • ER negative • HER-2 overexpression + HR positive • HER-2 positive + HER-2 overexpression
    5ms
    De-escalation of radiotherapy of infiltrating breast cancer: Myths and realities (PubMed, Bull Cancer)
    Patient selection for these approaches must be rigorous and depends partly on the technique chosen. Patients should be fully informed about the potential side effects of each technique.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 overexpression + HR positive
    6ms
    DAISY: Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis (clinicaltrials.gov)
    P2, N=186, Completed, UNICANCER | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Dec 2024
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 overexpression • HER-2 negative • HER-2 overexpression + HR positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    6ms
    Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2025 --> May 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel
    6ms
    GrannyFit: Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment (clinicaltrials.gov)
    P=N/A, N=200, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    HR positive • HER-2 overexpression • HER-2 overexpression + HR positive
    9ms
    NeoFit: Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P=N/A, N=300, Completed, Institut Curie | Trial completion date: Sep 2025 --> Mar 2025 | Trial primary completion date: Sep 2024 --> Mar 2025 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 overexpression • HER-2 overexpression + HR positive
    9ms
    Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> May 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel
    9ms
    Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer. (PubMed, Br J Cancer)
    Neurological burden at BM diagnosis independently predicts survival in BC patients. Our findings emphasise incorporating the symptom status in the prognostic evaluation and reassessing BM screening in high-risk patients during prospective clinical trials.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 overexpression • HER-2 negative • EGFR positive • HER-2 overexpression + HR positive